"instanceType","name","id","rationale","description","uuid:ID","label"
"StudyDesign","Study Design 1","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","62f8bff2-a959-456b-a341-3e510cb430a4",""
